share_log

Wedbush Reiterates Neutral on Zentalis Pharma, Maintains $4 Price Target

Benzinga ·  Mar 28 13:51

Wedbush analyst Robert Driscoll reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Neutral and maintains $4 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 223

Recommended

Write a comment